Novartis Community Update September 2022
In this September 2022 community update, Novartis Gene Therapies shares the latest updates on SMA Clinical Trial Program.
For more information please see the link below.
In this September 2022 community update, Novartis Gene Therapies shares the latest updates on SMA Clinical Trial Program.
For more information please see the link below.
Roche announces new two-year data from the JEWELFISH study evaluating Evrysdi (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at the time of enrolment. The data will be first presented at the 27th World Muscle Society (WMS) congress, 11-15 October 2022.
It will be also announced during the Roche PAG Scientific Meeting taking place during our 3rd Scientific Congress on Spinal Muscular Atrophy in Barcelona on Saturday, 22 October at 4 pm.
We are happy to announce that the 3rd International Scientific Congress on Spinal Muscular Atrophy, Barcelona, Spain, 21/10/2022-23/10/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s).
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Novartis Gene Therapies has just recently issued a community update about two acute liver failure cases in Russia and Kazakhstan reported back in August 2022.